0 27

Cited 0 times in

Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer

DC Field Value Language
dc.contributor.author김지수-
dc.contributor.author김현정-
dc.contributor.author윤미진-
dc.contributor.author이미수-
dc.contributor.author이승환-
dc.contributor.author최영득-
dc.date.accessioned2024-08-19T00:06:36Z-
dc.date.available2024-08-19T00:06:36Z-
dc.date.issued2024-05-
dc.identifier.issn1619-7070-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/200218-
dc.description.abstractPurpose: [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) has limitations in prostate cancer (PCa) detection owing to low glycolysis in the primary tumour. Recently, prostate-specific membrane antigen (PSMA) PET/CT has been useful for biochemical failure detection and radioligand therapy (RLT) guidance. However, few studies have evaluated its use in primary prostate tumours using PSMA and [18F]FDG PET/CT. This study aimed to evaluate [18F]PSMA-1007 and [18F]FDG PET/CT for primary tumour detection and understand the association of metabolic heterogeneity with clinicopathological characteristics at staging and postoperatively. Method: This prospective study included 42 index tumours (27 acinar and 15 ductal-dominant) in 42 patients who underwent [18F]PSMA-1007 and [18F]FDG PET/CT and subsequent radical prostatectomy. All patients were followed for a median of 26 mo, and serum prostate-specific antigen levels were measured every 3 mo to evaluate biochemical failure. One-way analysis of variance, Tukey's multiple comparison test, and Fisher's exact test were performed. Results: All 42 index tumours were detected on [18F]PSMA-1007 PET/CT, whereas only 15 were detected on [18F]FDG PET/CT (62.3% vs. 37.7%, p < 0.0001). A high SUVmax for [18F]PSMA-1007 was observed in tumours with high Gleason scores (GS 6-7 vs. GS 8-10; 12.1 vs. 20.1, p < 0.05). Tumours with [18F]FDG uptake were mostly ductal dominant (acinar-dominant 4/27; ductal-dominant; 11/15, p < 0.001), with lower [18F]PSMA-1007 uptake than tumours without [18F]FDG uptake (SUVmax 16.58 vs. 11.19, p < 0.001). There were 16.6% (7/42) of patients with pStage IV in whom the primary tumours were [18F]FDG positive. Biochemical failure was observed in 14.8% (4/27) of patients with [18F]FDG negative tumours but in 53.3% (8/15) of patients with [18F]FDG positive tumours (p = 0.013). Conclusions: [18F]PSMA-1007 PET/CT was superior to [18F]FDG PET/CT in detecting primary PCa. In contrast, tumours with [18F]FDG uptake are associated with larger size, a ductal-dominant type, and likely to undergo metastasis at staging and biochemical failure postoperatively.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-Verlag Berlin-
dc.relation.isPartOfEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAged-
dc.subject.MESHFluorodeoxyglucose F18*-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging*-
dc.subject.MESHNiacinamide / analogs & derivatives*-
dc.subject.MESHOligopeptides / chemistry-
dc.subject.MESHPositron Emission Tomography Computed Tomography*-
dc.subject.MESHPostoperative Period-
dc.subject.MESHProspective Studies-
dc.subject.MESHProstatic Neoplasms* / diagnostic imaging-
dc.subject.MESHProstatic Neoplasms* / pathology-
dc.subject.MESHProstatic Neoplasms* / surgery-
dc.subject.MESHRadiopharmaceuticals-
dc.titleCombination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentBioMedical Science Institute (의생명과학부)-
dc.contributor.googleauthorJisu Kim-
dc.contributor.googleauthorSeunghwan Lee-
dc.contributor.googleauthorDongwoo Kim-
dc.contributor.googleauthorHyun Jeong Kim-
dc.contributor.googleauthorKyeong Taek Oh-
dc.contributor.googleauthorSun Jung Kim-
dc.contributor.googleauthorYoung Deuk Choi-
dc.contributor.googleauthorFrederik L Giesel-
dc.contributor.googleauthorKlaus Kopka-
dc.contributor.googleauthorAlexander Hoepping-
dc.contributor.googleauthorMisu Lee-
dc.contributor.googleauthorMijin Yun-
dc.identifier.doi10.1007/s00259-023-06585-7-
dc.contributor.localIdA00969-
dc.contributor.localIdA01129-
dc.contributor.localIdA02550-
dc.contributor.localIdA05374-
dc.contributor.localIdA02938-
dc.contributor.localIdA04111-
dc.relation.journalcodeJ00833-
dc.identifier.eissn1619-7089-
dc.identifier.pmid38200396-
dc.identifier.urlhttps://link.springer.com/article/10.1007/s00259-023-06585-7-
dc.subject.keywordBiochemical failure-
dc.subject.keywordCancer metabolism-
dc.subject.keywordCancer staging-
dc.subject.keywordProstate-
dc.subject.keyword[18F]FDG-
dc.subject.keyword[18F]PSMA-1007 PET/CT-
dc.contributor.alternativeNameKim, Ji Su-
dc.contributor.affiliatedAuthor김지수-
dc.contributor.affiliatedAuthor김현정-
dc.contributor.affiliatedAuthor윤미진-
dc.contributor.affiliatedAuthor이미수-
dc.contributor.affiliatedAuthor이승환-
dc.contributor.affiliatedAuthor최영득-
dc.citation.volume51-
dc.citation.number6-
dc.citation.startPage1763-
dc.citation.endPage1772-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.51(6) : 1763-1772, 2024-05-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.